McKesson
MCK
910.33
-11.34
-1.23%
McKesson
US · MCK
#209 by market cap
Listed 1970
910.33
-11.34
-1.23%
Live - 5344 symbols - heartbeat 526s ago
· 2026-10-08 08:34
Pre-market
910.33
0.00%
After-hours
910.33
0.00%
Overnight
909.26
-0.12%
- Market cap
- 106.14B
- P/E (TTM)i
- 24.31
- P/Bi
- -25.03
- EPSi
- 38.55
- Div yieldi
- 0.36%
- 52W posi
- 69%
Reader sentiment
Are you bullish or bearish on MCK?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.16, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +12.36% YoY
Margins
- Gross margin
- 3.61%
- Operating margin
- 1.60%
- Net margin
- 1.18%
Key ratios & quality
- Enterprise valuei
- 108.97B
- PEG ratioi
- 2.39
- Altman Z-Scorei
- 6.16
PEG uses trailing P/E against the 3-year net income growth rate (10.18%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 214.32B | 231.05B | 238.23B | 263.97B | 276.71B | 308.95B | 359.05B | 403.43B |
| Gross profit | 11.75B | 12.02B | 12.15B | 13.13B | 12.36B | 12.83B | 13.32B | 14.55B |
| Selling & admin expenses | 8.44B | 9.18B | 8.85B | 10.54B | 7.78B | 8.66B | 8.51B | 8.10B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 3.32B | 2.84B | 3.30B | 2.59B | 4.58B | 4.17B | 4.82B | 6.45B |
| Pretax profit | 610.00M | 1.14B | -5.03B | 1.93B | 4.63B | 3.79B | 4.36B | 6.20B |
| Tax | 356.00M | 18.00M | -695.00M | 636.00M | 905.00M | 629.00M | 878.00M | 1.10B |
| Net profit | 255.00M | 1.12B | -4.34B | 1.29B | 3.72B | 3.16B | 3.48B | 5.10B |
| Basic EPS | 0 | 5 | -28 | 7 | 25 | 23 | 26 | 39 |
| Diluted EPS | 0.17 | 4.95 | -28.26 | 7.23 | 25.03 | 22.39 | 25.72 | 38.38 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 90.82B | 97.83B | 103.15B | 106.16B | 96.30B | 105.38B |
| Gross profit | 3.64B | 3.28B | 3.54B | 3.69B | 4.04B | 3.69B |
| Selling & admin expenses | 1.98B | 2.20B | 2.07B | 2.03B | 1.80B | 2.26B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.66B | 1.08B | 1.47B | 1.66B | 2.25B | 1.42B |
| Pretax profit | 1.52B | 1.05B | 1.40B | 1.63B | 2.13B | 1.31B |
| Tax | 209.00M | 220.00M | 232.00M | 380.00M | 270.00M | 276.00M |
| Net profit | 1.31B | 831.00M | 1.16B | 1.25B | 1.86B | 1.03B |
| Basic EPS | 10 | 6 | 9 | 10 | 14 | 5 |
| Diluted EPS | 10.01 | 6.25 | 8.92 | 9.59 | 13.71 | 5.15 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 38.47B | 42.22B | 45.38B | 46.23B | 44.29B | 47.97B | 55.40B | 57.21B |
| Cash & ST investments | 2.98B | 4.02B | 6.28B | 3.53B | 4.68B | 4.58B | 5.69B | 3.98B |
| Inventory | 16.71B | 16.73B | 19.25B | 18.70B | 19.69B | 21.14B | 23.00B | 24.21B |
| Total assets | 59.67B | 61.25B | 65.02B | 63.30B | 62.32B | 67.44B | 75.14B | 82.32B |
| Total current liabilities | 37.63B | 42.62B | 44.10B | 48.47B | 47.96B | 52.36B | 61.60B | 67.02B |
| Short-term debt | 330.00M | 1.41B | 1.13B | 1.10B | 1.27B | 345.00M | 1.45B | 1.55B |
| Long-term debt | 7.27B | 6.34B | 6.41B | 5.08B | 4.63B | 5.58B | 4.46B | 5.26B |
| Total liabilities | 49,992,000,000.00 | 54,536,000,000.00 | 63,569,000,000.00 | 65,090,000,000.00 | 63,810,000,000.00 | 69,042,000,000.00 | 76,834,000,000.00 | 83,157,000,000.00 |
| Total equity | 9.68B | 6.71B | 1.45B | -1.79B | -1.49B | -1.60B | -1.69B | -834.00M |
| Retained earnings | 12.41B | 13.02B | 8.20B | 9.03B | 12.30B | 14.98B | 17.92B | 22.29B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 55.40B | 56.80B | 59.89B | 59.70B | 57.21B | 62.84B |
| Cash & ST investments | 5.69B | 2.42B | 4.00B | 2.96B | 3.98B | 5.16B |
| Inventory | 23.00B | 25.07B | 26.13B | 27.07B | 24.21B | 26.26B |
| Total assets | 75.14B | 81.31B | 84.16B | 84.19B | 82.32B | 88.33B |
| Total current liabilities | 61.60B | 64.33B | 68.03B | 68.13B | 67.02B | 70.36B |
| Short-term debt | 1.45B | 1.55B | 2.03B | 1.42B | 1.55B | 1.59B |
| Long-term debt | 4.46B | 6.53B | 6.01B | 5.43B | 5.26B | 8.43B |
| Total liabilities | 76,834,000,000.00 | 82,174,000,000.00 | 84,738,000,000.00 | 84,289,000,000.00 | 83,157,000,000.00 | 89,631,000,000.00 |
| Total equity | -1.69B | -863.00M | -578.00M | -99.00M | -834.00M | -1.30B |
| Retained earnings | 17.92B | 18.62B | 19.62B | 20.71B | 22.29B | 22.81B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 4.04B | 4.37B | 4.54B | 4.43B | 5.16B | 4.31B | 6.09B | 6.16B |
| Depreciation & amortization | 949.00M | 922.00M | 887.00M | 760.00M | 608.00M | 635.00M | 636.00M | 729.00M |
| Free cash flow | 3.48B | 3.87B | 3.90B | 3.90B | 4.60B | 3.63B | 5.23B | 5.41B |
| Dividends paid | -292.00M | -294.00M | -276.00M | -277.00M | -292.00M | -314.00M | -345.00M | -381.00M |
| Stock buybacks / issuance | -1.56B | -1.82B | -650.00M | -3.30B | -3.48B | -2.91B | -3.05B | -4.66B |
| Ending cash balance | 2.98B | 4.02B | 6.28B | 3.53B | 4.68B | 4.58B | 5.69B | 3.98B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 7.75B | -918.00M | 2.42B | 1.23B | 3.42B | -220.00M |
| Depreciation & amortization | 151.00M | 157.00M | 188.00M | 188.00M | 196.00M | 195.00M |
| Free cash flow | 7.47B | -1.11B | 2.22B | 1.06B | 3.24B | -372.00M |
| Dividends paid | -91.00M | -90.00M | -89.00M | -101.00M | -101.00M | -102.00M |
| Stock buybacks / issuance | -272.00M | -559.00M | -790.00M | -665.00M | -2.65B | -2.51B |
| Ending cash balance | 5.69B | 2.42B | 4.00B | 2.96B | 3.98B | 5.16B |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 0.38 | 13.65 | -179.02 | -- | -- | -- | -- | -- |
| ROA %i | 0.06 | 1.49 | -7.19 | 1.74 | 5.67 | 4.63 | 4.62 | 6.05 |
| ROIC %i | 1.19 | 7.27 | -36.54 | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | 19.24 | 18.40 | -22.74 | -- | -- | -- | -- | -- |
| EBIT margin %i | 0.41 | 0.60 | -2.02 | 0.80 | 1.76 | 1.31 | 1.29 | 1.60 |
| FCF / sales %i | 1.62 | 1.67 | 1.64 | 1.48 | 1.66 | 1.17 | 1.46 | 1.34 |
| Current ratioi | 1.02 | 0.99 | 1.03 | 0.95 | 0.92 | 0.92 | 0.90 | 0.85 |
| Quick ratioi | 0.56 | 0.56 | 0.58 | 0.46 | 0.50 | 0.50 | 0.51 | 0.48 |
| Debt / assetsi | 12.73 | 15.35 | 14.47 | 11.92 | 11.71 | 10.96 | 9.84 | 10.46 |
| LT debt / equityi | 89.76 | 157.01 | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 3.31 | 5.59 | -22.20 | 11.83 | 19.67 | 16.04 | 17.45 | 26.11 |
| Revenue CAGR (3Y) %i | 3.94 | 5.19 | 4.57 | 7.19 | 6.20 | 9.05 | 10.80 | 13.39 |
| Net income CAGR (3Y) %i | -75.31 | -43.80 | -- | 219.99 | 58.15 | -- | 43.55 | 10.18 |
| FCF CAGR (3Y) %i | 5.12 | -2.57 | 1.19 | 3.87 | 5.96 | -2.40 | 10.26 | 5.55 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | 4.62 | 4.14 | 5.15 | 5.59 | 6.05 | 5.41 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 1.29 | 1.21 | 1.40 | 1.46 | 1.60 | 1.64 |
| FCF / sales %i | 1.46 | 1.50 | 1.55 | 2.42 | 1.34 | 1.50 |
| Current ratioi | 0.90 | 0.88 | 0.88 | 0.88 | 0.85 | 0.89 |
| Quick ratioi | 0.51 | 0.48 | 0.47 | 0.46 | 0.48 | 0.50 |
| Debt / assetsi | 9.84 | 12.22 | 11.64 | 10.24 | 10.46 | 13.25 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 17.45 | 19.10 | 23.07 | 25.20 | 26.11 | 24.48 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- North American Pharmaceutical is the largest reported line at 82.34% of revenue, across 4 reported segments.
- The next-largest line, Oncology & Multispecialty, is a distant second at 13.50% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
North American Pharmaceutical82.34%
Oncology & Multispecialty13.50%
Medical-Surgical Solutions2.68%
Prescription Technology Solutions1.49%
Quote time 2026-10-08 08:34:14 · For reference only, not investment advice and not tailored to your situation.